XML 69 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Compensation Expense and Related Income Tax Benefit The compensation expense from the Company’s share-based compensation plans and associated income tax benefit, excluding the effects of excess tax benefits or shortfalls, were included in the Consolidated Statements of Operations as follows (in millions):
 Year Ended December 31,
Compensation costs and related income tax benefit202120202019
Cost of sales$8 $6 $4 
Selling and marketing26 16 17 
Research and development28 16 16 
General and administration31 21 23 
Total compensation expense$93 $59 $60 
Income tax benefit$14 $9 $9 
Summary of Equity Awards Activity A summary of the Company’s restricted and performance stock-settled awards for the years ended December 31, 2021, 2020 and 2019 is as follows:
Year Ended December 31, 2021
RSUsPSUsRSAsPSAs
UnitsWeighted-Average Grant Date Fair ValueUnitsWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair Value
Outstanding at beginning of year— $— — $— 318,565 $228.08 126,022 $199.77 
Granted134,419 518.39 38,393 482.42 6,005 486.02 — — 
Released(674)489.16 — — (159,702)212.33 (49,236)160.11 
Forfeited(3,736)509.58 (702)482.42 (10,546)239.78 (2,754)236.18 
Outstanding at end of year130,009 $518.80 37,691 $482.42 154,322 $253.54 74,032 $225.34 

Year Ended December 31, 2020
RSAsPSAs
SharesWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair Value
Outstanding at beginning of year434,641 $151.52 170,749 $144.47 
Granted178,150 265.06 98,820 239.79 
Released(275,318)133.43 (131,943)160.18 
Forfeited(18,908)199.04 (11,604)194.23 
Outstanding at end of year318,565 $228.08 126,022 $199.77 

Year Ended December 31, 2019
RSAsPSAs
SharesWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair Value
Outstanding at beginning of year657,724 $93.45 259,727 $86.41 
Granted170,502 204.26 150,224 206.04 
Released(372,075)73.71 (231,513)120.86 
Forfeited(21,510)141.29 (7,689)102.42 
Outstanding at end of year434,641 $151.52 170,749 $144.47 
Summary of SARs Activity A summary of the Company’s SARs is as follows:
202120202019
SARsSARsWeighted-Average Grant Date Exercise PriceSARsWeighted-Average Grant Date Exercise PriceSARsWeighted-Average Grant Date Exercise Price
Outstanding at beginning of year638,124 $113.98 896,923 $89.05 1,261,185 $75.71 
Granted— — 69,742 253.62 70,141 205.12 
Exercised(159,035)89.87 (295,770)67.96 (395,015)66.82 
Forfeited(4,938)213.80 (31,193)149.09 (39,388)92.72 
Expired— — (1,578)166.52 — — 
Outstanding at end of year474,151 $121.05 638,124 $113.98 896,923 $89.05 
Exercisable at end of year383,273 $97.29 417,856 $81.88 489,357 $70.37 
Summary of Information for SARs Outstanding
The following table summarizes information about SARs outstanding as of December 31, 2021:
OutstandingExercisable
Aggregate intrinsic value (in millions)$225$191
Weighted-average remaining contractual life (in years)3.63.3
Summary of Outstanding and Exercisable Options
A summary of the Reflexis Replacement Options outstanding is as follows:
 20212020
Reflexis Replacement OptionsOptionsWeighted-Average Exercise PriceOptionsWeighted-Average Exercise Price
Outstanding at beginning of year34,424 $58.09 — $— 
Granted— — 38,228 57.82 
Exercised(9,318)59.68 (3,408)55.79 
Forfeited(1,529)63.01 (396)52.14 
Outstanding at end of year23,577 $57.06 34,424 $58.09 
Exercisable at end of year18,232 $54.50 6,716 $56.77 
The following table summarizes information related to the Reflexis Replacement Options outstanding as of December 31, 2021:
OutstandingExercisable
Aggregate intrinsic value (in millions)$13 $10
Weighted-average remaining contractual life (in years)6.35.9